PMID- 33949793
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210701
IS  - 2162-3279 (Electronic)
VI  - 11
IP  - 6
DP  - 2021 Jun
TI  - Persistence with medical treatment for Wilson disease in China based on a single 
      center's survey research.
PG  - e02168
LID - 10.1002/brb3.2168 [doi]
LID - e02168
AB  - BACKGROUND: Wilson's disease (WD) is one of the few hereditary diseases that can 
      be successfully treated with medicines. We conduct this survey research to assess 
      treatment persistence among patients with WD and try to identify what factors 
      affect the treatment persistence. METHODS: We employed WeChat which is the most 
      popular social software in China to carry out this anonymous questionnaire 
      research. The questionnaire included medication adherence scale. We also 
      collected available medical records related to demographic and clinical 
      characteristics. All the patients were divided into group of persistence with 
      drug treatment (PDT) and nonpersistence with drug treatment (n-PDT). RESULTS: We 
      collected 242 qualified questionnaires. Only 66.5% of patients were PDT during 
      the mean 12.6 years of follow-up. In PDT group, better outcomes were observed: 
      improvement (78.3%) and no change (16.1%) versus those in n-PDT (55.6%; and 
      28.4%, respectively). In PDT group, only nine patients deteriorated (6.8%) in 
      comparison with 13 patients in n-PDT (16.0%). The adverse events (AEs) in PDT 
      group were significantly less than those in n-PDT group. There were no 
      significant differences in clinical type, gender, age, education level, and 
      family knowledge about WD between the two groups. There were significant 
      differences in AEs and family position toward treatment. CONCLUSION: Medication 
      Adherence of Chinese WD patients was low. One third of the patients (33.5%) were 
      unable to PDT, and it had an important negative effect on clinical outcome. AEs 
      and family support had an important impact on treatment persistence.
CI  - (c) 2021 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
FAU - Zhou, Zhi-Hua
AU  - Zhou ZH
AUID- ORCID: 0000-0001-6262-6365
AD  - Department of Neurology, The first affiliated hospital, School of Clinical 
      Medicine of Guangdong Pharmaceutical University, Guangzhou, China.
FAU - Wu, Yun-Fan
AU  - Wu YF
AD  - The Second School of Clinical Medicine, Southern Medical University, Guangdong 
      Second Provincial General Hospital, Guangzhou, China.
FAU - Yan, Yan
AU  - Yan Y
AD  - Wilson Disease Centre, Hospital Affiliated to Institute of Neurology, Anhui 
      University of Chinese Traditional Medicine, Hefei, China.
FAU - Liu, Ai-Qun
AU  - Liu AQ
AD  - Department of Neurology, The first affiliated hospital, School of Clinical 
      Medicine of Guangdong Pharmaceutical University, Guangzhou, China.
FAU - Yu, Qing-Yun
AU  - Yu QY
AD  - Department of Neurology, The first affiliated hospital, School of Clinical 
      Medicine of Guangdong Pharmaceutical University, Guangzhou, China.
FAU - Peng, Zhong-Xing
AU  - Peng ZX
AD  - Department of Neurology, The first affiliated hospital, School of Clinical 
      Medicine of Guangdong Pharmaceutical University, Guangzhou, China.
FAU - Wang, Gong-Qiang
AU  - Wang GQ
AD  - Wilson Disease Centre, Hospital Affiliated to Institute of Neurology, Anhui 
      University of Chinese Traditional Medicine, Hefei, China.
FAU - Hong, Ming-Fan
AU  - Hong MF
AD  - Department of Neurology, The first affiliated hospital, School of Clinical 
      Medicine of Guangdong Pharmaceutical University, Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210505
PL  - United States
TA  - Brain Behav
JT  - Brain and behavior
JID - 101570837
SB  - IM
MH  - China
MH  - *Hepatolenticular Degeneration/drug therapy
MH  - Humans
PMC - PMC8213922
OTO - NOTNLM
OT  - Wilson's disease
OT  - medicine adherence
OT  - nonpersistence with drug treatment
OT  - persistence with drug treatment
COIS- None declared.
EDAT- 2021/05/06 06:00
MHDA- 2021/07/02 06:00
PMCR- 2021/05/05
CRDT- 2021/05/05 09:21
PHST- 2021/03/08 00:00 [revised]
PHST- 2021/01/05 00:00 [received]
PHST- 2021/04/17 00:00 [accepted]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
PHST- 2021/05/05 09:21 [entrez]
PHST- 2021/05/05 00:00 [pmc-release]
AID - BRB32168 [pii]
AID - 10.1002/brb3.2168 [doi]
PST - ppublish
SO  - Brain Behav. 2021 Jun;11(6):e02168. doi: 10.1002/brb3.2168. Epub 2021 May 5.